SPECIAL NOTICE
A -- TECHNOLOGY/BUSINESS OPPORTUNITY TARGETED ANTIMICROBIALS BASED ON RECOMBINANT MURAMIDASES
- Notice Date
- 1/22/2014
- Notice Type
- Special Notice
- NAICS
- 238990
— All Other Specialty Trade Contractors
- Contracting Office
- Department of Energy, Lawrence Livermore National Laboratory (DOE Contractor), Industrial Partnerships & Commercialization, 7000 East Avenue, L-795, Livermore, California, 94550
- ZIP Code
- 94550
- Solicitation Number
- FBO283-14
- Archive Date
- 2/25/2014
- Point of Contact
- Connie L Pitcock, Phone: 925-422-1072
- E-Mail Address
-
pitcock1@llnl.gov
(pitcock1@llnl.gov)
- Small Business Set-Aside
- N/A
- Description
- TECHNOLOGY/BUSINESS OPPORTUNITY TARGETED ANTIMICROBIALS BASED ON RECOMBINANT MURAMIDASES Opportunity : Lawrence Livermore National Laboratory (LLNL), operated by the Lawrence Livermore National Security (LLNS), LLC under contract no. DE-AC52-07NA27344 (Contract 44) with the U.S. Department of Energy (DOE), is offering the opportunity to license intellectual property rights to commercialize its technology Targeted Antimicrobials based on Recombinant Muramidases. Background : Development of bacterial resistance to antibiotics has become a considerable threat to human health. Because bacteria can adapt so quickly to new drugs, better approaches are needed to continue to develop novel strategies and tactics to combat these pathogenic bacteria. Microbe-specific muramidase proteins have the potential for use to treat infections caused by specific groups of microbes. LLNL has synthesized and purified milligram quantities of two muramidases and developed a cell-based lysis assay to test these proteins.It has demonstrated that these purified muramidases lyse B. anthracis Sterne when applied externally to these cells. Their methods can be generally applied to identify and rapidly screen for similar lytic proteins encoded by other bacterial pathogens that could be further developed as antimicrobial compounds to destroy these pathogens. Description : LLNL researchers have combined a novel approach or using bioinformatics with cell-free expression to identify and characterize a class of proteins that kill Gram-positive bacteria with extremely high specificity. The class of proteins is collectively known as muramidases and possess bacterial lytic activity. Muramidases generally represent a potential class of novel antimicrobials for use against other Gram positive and, potentially, against Gram-negative infectious microorganisms. Strategies for effectively delivering these antimicrobial agents are being developed. These lytic proteins attack for the outside of the cells and circumvent mechanisms of antibiotic resistance that are found in many of the so-called drug-resistant superbugs. As such, they should be effective against these antibiotic resistant pathogens. These lytic proteins can also be used to specifically lyse target bacteria in complex mixtures resulting in rapid, specific, and quantitative release of DNA and other macromolecules from complex mixtures, facilitating development of automated assays that do not require physical disruption techniques for release of these diagnostic molecules. Advantages : The competitive advantages of LLNL's targeted antimicrobials based on recombinant muramidases include: A novel approach to attacking pathogens of interest by the rapid production of recombinant lytic proteins encoded by the pathogen's own genome. A novel pipeline for rapidly identifying and producing new antimicrobials capable of specifically killing known bacterial pathogens. Recombinant compounds that mimic a known naturally occurring mechanism for bacteriophage release from the bacteria and are known to be required for bacterial cell wall synthesis and metabolism and can be rapidly produced in milligram quantities. Provides an essential component to the scientific community that enables the rapid lysis of many different bacterial species including those classes that are difficult to lyse such as the bacilli. Technological leap forward for cell lysis approaches needed to improve automated detection and characterization methods that rely on real-time aerosol analysis of bacteria and bacterial pathogens. Potential Applications : Potential applications for use include: Basic biochemical research Removing live bacteria for spore isolation Treatment and removal of select bacterial pathogens Antibody based detection of pathogens Surface treatment of instrumentation and hard surfaces Cleaning surgical instruments DNA preparative reagent to lyse bacteria Additive to topical lotions as antimicrobial agent Additive to bandages to kill bacterial pathogens Fermentation to remove undesirable bacteria, food additive, or wash Reagent to destroy biofilms Species-specific antimicrobials that destroy specific antibiotic-resistant pathogens without the use of broad-spectrum antibiotics Development Status: LLNL has filed for patent protection on this technology. LLNL is seeking industry partners with a demonstrated ability to bring such inventions to the market. Moving critical technology beyond the Laboratory to the commercial world helps our licensees gain a competitive edge in the marketplace. All licensing activities are conducted under policies relating to the strict nondisclosure of company proprietary information. Please visit the IPO website at https://ipo.llnl.gov/?q=resources-industry-partnering_guidelines for more information on working with LLNL and the industrial partnering and technology transfer process. Note: THIS IS NOT A PROCUREMENT. Companies interested in commercializing LLNL's Targeted Antimicrobials based on Recombinant Muramidases technology should provide a written statement of interest that includes the following: 1. Company Name and address. 2. The name, address, and telephone number of a point of contact. •3. A description of corporate expertise and facilities relevant to commercializing this technology. Written responses should be directed to: Lawrence Livermore National Laboratory Industrial Partnerships Office P.O. Box 808, L-795 Livermore, CA 94551-0808 Attention: FBO 283-14 Please provide your written statement within thirty (30) days from the date this announcement is published to ensure consideration of your interest in LLNL's Targeted Antimicrobials based on Recombinant Muramidases.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/DOE/LLNL/LL/FBO283-14/listing.html)
- Record
- SN03271852-W 20140124/140122233914-5b02da7f3ba6c31fb0f18f406475c2b1 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |